CytoReason Secures $80M Series C Funding to Scale AI Disease Models nextdigitalhealth.com

CytoReason, a biotechnology company leveraging computational disease models to help biopharma companies make informed decisions through a data-driven approach, has raised $80 million in a series C funding round to scale its AI-powered disease models.

https://nextdigitalhealth.com/funding-news/cytoreason-secures-80m-series-c-funding-to-scale-ai-disease-models/